Breadcrumb
BA Part B
Blue Advantage Part B Provider-Administered Drug Precertification Program
Blue Advantage covers certain Part B medications that are given by your healthcare provider in an office/infusion clinic, outpatient facility or home setting. The medications covered under Part B must be medically necessary according to the guidelines and policies established by the Centers for Medicare & Medicaid Services (CMS).
Precertification is a process by which a provider is required to obtain approval for a medication or service before the medication or service will be covered.
Click here for the list of medications that require precertification.
Part B Step Therapy
Blue Advantage Part B Drug Step Therapy Program
Effective January 1, 2026, certain drugs in the Part B Drug Step Therapy Program are changing from non-preferred to preferred status*. Review the list below to determine which drugs require precertification or are subject to step therapy (i.e., they will be approved with a valid prescription) for Blue Advantage patients.
Part B Chart
| Preferred Products
(No Step Therapy or Precertification Required)
|
Non-Preferred Products
(Subject to Step Therapy and Precertification Requirements)
|
|
|---|---|---|
| Rituximab |
Riabni |
Rituxan |
| Trastuzumab |
Kanjinti |
Herceptin |
| Bevacizumab |
Mvasi |
Alymsys |